Tessa Therapeutics Appoints Ms. Jennifer Butler as Chief Commercial Officer

Date: 20 Jul 2017 | Download Press Release (PDF)

SINGAPORE – 20 July 2017 – Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the appointment of Ms. Jennifer Butler as Chief Commercial Officer. In her new role, she will be responsible for driving the global launch and commercialization strategy of Tessa’s advanced T cell therapy pipeline, including the company’s lead product, TT10, which is currently in a global Phase III trial for the treatment of nasopharyngeal carcinoma. Ms. Butler will be based in the US and will be leading the expansion of the company’s US business operations.

“The addition of Jennifer to our global executive team will be instrumental as we prepare our organization for regulatory filings and commercial launches in the coming years,” said Andrew Khoo, co-founder and CEO of Tessa Therapeutics. “Her strong commercialization expertise and wealth of experience in bringing novel drugs and therapies to market will be invaluable to us as we progress our advanced immuno-oncology portfolio.”

Ms. Butler has nearly 20 years of pharmaceutical and biotechnology experience across several therapeutic areas and functions, including global marketing, sales, and corporate strategy. Prior to joining the company, she spent 11 years in roles of increasing responsibility at AstraZeneca and MedImmune, the Biologics Division of AstraZeneca.  Ms. Butler most recently served as the head of global launch preparation and commercial strategy for AstraZeneca’s late-stage immuno-oncology programs, including recently launched Imfinzi™ / durvalumab (PD-L1).

“I am delighted to join Tessa as the company enters an exciting growth phase. I look forward to working with Tessa’s dynamic and passionate team to drive the company’s launch and commercialization strategy,” said Jennifer. “Tessa’s virus specific T cell platform is showing compelling results in the treatment of solid tumors and I am thrilled to play a role in bringing these unique and critically important therapies to patients.”

About Tessa Therapeutics

Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa’s lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world’s largest Phase III T cell immunotherapy trial for any cancer indication. The company has built up robust operational and supply chain capabilities to successfully deliver autologous T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled the company to create a fully-integrated approach to the treatment of cancer with immunotherapy.

For more information on Tessa, please visit www.tessacell.com.

Media Contact
Brunswick Group
Will Carnwath, CJ Lin
+65 6426 8188

Investor Contact
Trout Group
Pete Rahmer
+1 646-378-2973